Vaccines

06 Nov 2007 GlobeImmune Announces Presentation of Results from a Randomized Phase 1b Study of the GI-5005 Tarmogen in Patients with Chronic Hepatitis C Infection
05 Nov 2007 Curalogic updates from its Phase III clinical study with the ragweed product
03 Nov 2007 IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
03 Nov 2007 IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients
02 Nov 2007 Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
24 Oct 2007 Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
19 Oct 2007 Sanofi Pasteur receives FDA approval of meningococcal vaccine for children
18 Oct 2007 Interim Safety Data Favorable for Vical's Phase 2 Trial of DNA Vaccine Against CMV
11 Oct 2007 Pharmexa provides update on the development of GV1001
09 Oct 2007 Amorfix Life Sciences develops two vaccines that extend life in Amyotrophic Lateral Sclerosis (ALS) animal model
02 Oct 2007 U.S. Food & Drug Administration approves CSL influenza virus vaccine, for marketing in the U.S.
28 Sep 2007 Phylogica signs asthma research agreement
26 Sep 2007 immatics launches Phase 2 study on cancer vaccine IMA901
26 Sep 2007 VaxInnate Initiates Phase I Clinical Study of M2e Universal Influenza Vaccine
26 Sep 2007 Twinstrand Therapeutics Inc. Files IND Application For Immunogen in Ricin Antidote Study
22 Sep 2007 Vaccination and Enrollment Are Discontinued in Phase II Trials of Merck's Investigational HIV Vaccine Candidate
20 Sep 2007 FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
20 Sep 2007 Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
19 Sep 2007 Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 Field Study
19 Sep 2007 Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at Low Dosage
12 Sep 2007 Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
12 Sep 2007 Oxford BioMedica Reaches First Milestone in TroVax(T) Collaboration with Sanofi-Aventis
12 Sep 2007 Opexa Therapeutics Gives Update on Phase IIb Trial of Tovaxin® for Treatment of Multiple Sclerosis
11 Sep 2007 TapImmune Inc. Announces Initiation of Testing on Novel Cancer Vaccine
11 Sep 2007 GenVec to Develop New Malaria Vaccine for the U.S Military

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top